SCHEMBL2799537

SCHEMBL2799537

CCS(=O)(=O)NC(=O)c1cnn2c(Nc3cc(C)ccc3F)c(C(=O)N3CCC(c4ccc(F)c(F)c4)CC3)cnc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.36
FASN P49327 4/20 0.34
USP5 P45974 1/20 0.34
EGLN1 Q9GZT9 2/20 0.34
SPR P35270 2/20 0.34
IRAK4 Q9NWZ3 2/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 1/20 0.33
SCN9A Q15858 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
DPP4 P27487 1/20 0.33
KCNH2 Q12809 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
USP2 O75604 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799817 0.96 FASN (0.36) RECQLFASNSPRIRAK4SCN9A
SCHEMBL2801670 0.94 FASN (0.39) RECQLFASNEGLN1ALDH1A1LMNA
SCHEMBL2800842 0.93 ALDH1A1 (0.38) RECQLFASNEGLN1SPRALDH1A1
SCHEMBL2802313 0.92 EGLN1 (0.35) RECQLFASNEGLN1SPRIRAK4
SCHEMBL2803063 0.92 FASN (0.39) FASNEGLN1ALDH1A1KDM4EHPGD
SCHEMBL2801212 0.89 DHODH (0.37) FASNEGLN1SPRALDH1A1KDM4E
SCHEMBL2801339 0.89 TP53 (0.38) IRAK4SCN9ALMNATP53MAPT
SCHEMBL2803803 0.88 FASN (0.40) FASNALDH1A1LMNATP53MAPT
SCHEMBL2802831 0.87 KDM4E (0.40) RECQLALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2802285 0.87 FASN (0.35) FASNSPRIRAK4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 RECQL 690/4885FASN 4286/4885USP5 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.